6-氨基-2-硫代-1,2-二氢-5-嘧啶甲醛 | 105161-35-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 6-氨基-2-硫代-1,2-二氢-5-嘧啶甲醛
• 英文名称: 4-amino-2-sulfanylpyrimidine-5-carbaldehyde
• 英文别名: 5-formylthiocytosine；4-amino-2-sulfanylpyrimidine-5-carboxaldehyde；6-amino-2-sulfanylidene-1H-pyrimidine-5-carbaldehyde
• CAS: 105161-35-1
• 化学式: C₅H₅N₃OS
• 分子量: 155.18
• InChiKey: ZBMSFARLXYLDRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  99.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  6-氨基-2-硫代-1,2-二氢-5-嘧啶甲醛 在 三丁基膦 、 potassium carbonate 、 偶氮二甲酸二乙酯 作用下， 以 N-甲基吡咯烷酮 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 168.0h， 生成 6-(2,4-difluorophenoxy)-2-methylsulfanyl-8-(3-methylsulfanylpropyl)-8H-pyrido[2,3-d]pyrimidin-7-one
  参考文献：
  名称：

  Discovery of 6-(2,4-Difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Pamapimod) and 6-(2,4-Difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as Orally Bioavailable and Highly Selective Inhibitors of p38α Mitogen-Activated Protein Kinase

  摘要：

  The development of a new series of p38 alpha inhibitors resulted in the identification of two clinical candidates, one of which was advanced into a phase 2 clinical study for rheumatoid arthritis. The original lead, an lck inhibitor that also potently inhibited p38a, was a screening hit from our kinase inhibitor library. This manuscript describes the optimization of the lead to p38-selective examples with good pharmacokinetic properties.

  DOI：

  10.1021/jm101423y
• 作为产物：
  描述：

  (2E)-3-(二甲基氨基)-2-甲酰基丙烯腈 、 硫脲 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 5.0h， 以55%的产率得到6-氨基-2-硫代-1,2-二氢-5-嘧啶甲醛
  参考文献：
  名称：

  Synthesis with Nitriles: 92. Synthesis of 5-Formylcytosine Derivatives

  摘要：

  The reactivity of 3-dimethylamino-2-formylpropenenitrile (1) with various amino compounds is studied. Thus, condensation of 1 with anilines gives the corresponding azomethines (2a-c). Reaction of 1 with thiourea and guanidne resp., leads to 5-formylthiocytosine (3) and 2-amino-5-cyanopyrimidine (4). The 2-formyl-3-ureidopropenenitriles (5a-i) can be obtained by reaction of 1 with urea and substituted ureas. 5a-i can easily be cyclized to 3-substituted 5-formylcytosines (6-e). Condensation of 6 with aniline, benzylamine and phenylhydrazine leads to the azomethines (7a-i). Pyrido [ 2,3-d ] pyrimidine-6-carbonitriles (8a, 8b, Sd and 83) are obtained by reaction of 6 with malononitrile.

  DOI：

  10.3987/com-93-6416

文献信息

• 6-Substituted pyrido-pyrimidines
  申请人：——

  公开号：US20030171584A1

  公开（公告）日：2003-09-11

  The present invention provides compounds of the Formula I and II: 1 wherein R 1 , R 3 , W, Z, X 1 , X 2 , Ar 1 , R 8 and R 9 are as defined herein, and methods and intermediates for their preparation and uses thereof.

  本发明提供了化合物I和II的结构：其中R1、R3、W、Z、X1、X2、Ar1、R8和R9如本文所定义，并提供它们的制备方法和中间体以及它们的用途。
• [EN] 6-ALKOXY-PYRIDO-PYRIMIDINES AS P-38 MAP KINASE INHIBITORS<br/>[FR] 6-ALCOXY-PYRIDO-PYRIMIDINES UTILISEES COMME INHIBITEURS DE LA MAP KINASE P-38
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004014907A1

  公开（公告）日：2004-02-19

  The present invention provides compounds of Formula (I), wherein R1 is alkyl, cycloalkyl, cycloakylalkyl, or -CH2-alkenyl, X1 is O, NH, N(alkyl), S or -C(=O), Z is N or CH; and R2 and R3 are as defined herein, pharmaceutical compositions comprising same, and methods for their use.

  本发明提供了式（I）的化合物，其中R1是烷基、环烷基、环烷基烷基或-CH2-烯基，X1是O、NH、N（烷基）、S或-C（=O），Z是N或CH；以及R2和R3如本文所定义，包括相同的药物组合物，并用于它们的方法。
• 7-oxo-pyridopyrimidines (II)
  申请人：——

  公开号：US20020055513A1

  公开（公告）日：2002-05-09

  The present invention provides compounds of the formula: 1 a prodrug or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 and Ar 1 are those defined herein, and methods for preparation and uses thereof.

  本发明提供了以下公式的化合物：1a前体或其药用可接受的盐，其中R1、R2、R3和Ar1是在此定义的，以及其制备方法和用途。
• 6-alkoxy-pyrido-pyrimidines
  申请人：Goldstein Michael David

  公开号：US20060276646A1

  公开（公告）日：2006-12-07

  The present invention provides compounds of the Formula I: wherein R 1 is alkyl, cycloalkyl, cycloallkylalkyl, or —CH 2 -alkenyl, X 1 is O, NH, N(alkyl), S or —C(═O), Z is N or CH; and R 2 and R 3 are as defined herein, pharmaceutical compositions comprising same, and methods for their use.

  本发明提供了一种式子为I的化合物：其中R1为烷基，环烷基，环烷基烷基或—CH2-烯基，X1为O，NH，N(烷基)，S或—C(═O)，Z为N或CH；而R2和R3如此定义，包括该化合物的药物组成物和使用它们的方法。
• 6-Alkoxy-pyrido-pyrimidines
  申请人：Goldstein Michael David

  公开号：US20070167484A1

  公开（公告）日：2007-07-19

  The present invention provides compounds of the Formula I: wherein R 1 is allyl, cycloalkyl, cycloalkylalkyl, or —CH 2 -alkenyl, X 1 is O, NH, N(alkyl), S or —C(═O), Z is N or CH; and R 2 and R 3 are as defined herein, pharmaceutical compositions comprising same, and methods for their use.

  本发明提供了式I的化合物：其中R1是烯丙基，环烷基，环烷基烷基或—CH2-烯烃基，X1是O，NH，N（烷基），S或—C（═O），Z是N或CH；以及R2和R3如本文所定义，包含它们的制药组合物和使用它们的方法。